ENZENE BIOSCIENCES - GLP-1 Receptor Agonist Preparation Process Patent
Summary
The USPTO granted patent US12600759B2 to Enzene Biosciences Limited covering processes for preparing glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs. The patent specifically encompasses processes for preparing liraglutide, D-liraglutide, semaglutide, and D-semaglutide in substantially pure form. The application (17440127), filed on March 19, 2020, contains 4 claims and covers both solid and solution phase preparation methods.
What changed
USPTO granted patent US12600759B2 to Enzene Biosciences Limited covering processes for preparing GLP-1 receptor agonists including liraglutide, D-liraglutide, semaglutide, and D-semaglutide in substantially pure form. The patent covers both solid and solution phase preparation methods for these pharmaceutical compounds.
Manufacturers developing or producing GLP-1 receptor agonist products should evaluate their manufacturing processes against the claims of this patent to identify potential infringement risks. Companies may need to explore licensing arrangements with Enzene Biosciences or consider alternative synthesis routes to avoid patent claims.
What to do next
- Monitor for potential patent enforcement actions
- Review product manufacturing processes for potential infringement
- Consult IP counsel regarding licensing opportunities
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs
Grant US12600759B2 Kind: B2 Apr 14, 2026
Assignee
ENZENE BIOSCIENCES LIMITED
Inventors
Sandip Adak, Manoj Bonte, Chandrakant Kulkarni, Swamy Veeranarayana, Nivrutti Jogdand
Abstract
The present invention relates to the processes for preparing glucagon-like peptide-1 (glp-1) receptor agonists and their analogs. The present invention further relates to processes for preparing liraglutide, D-liraglutide, semaglutide and D-semaglutide. The present invention specifically relates to processes for preparing glucagon-like peptide-1 (glp-1) agonist and their analogs, wherein the liraglutide, D-liraglutide, semaglutide and D-semaglutide produced are substantially pure. The present invention also relates to preparation of glucagon-like peptide-1 (glp-1) agonist and their analogs by solid and solution phase method.
CPC Classifications
C07K 14/605 C07K 1/061 C07K 1/10 C07K 5/06095 C07K 5/06104 C07K 1/14 A61K 38/00 A61P 3/10
Filing Date
2020-03-19
Application No.
17440127
Claims
4
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.